Circulating adiponectin reflects severity of liver disease but not insulin sensitivity in liver cirrhosis

Journal of Internal Medicine

Volumn 258, Issue 3, 2005, Pages 274-280

  Kaser, S ^a   Moschen, A ^a   Kaser, A ^a   Ludwiczek, O ^a   Ebenbichler, C F ^a   Vogel, W ^a   Jaschke, W ^a   Patsch, J R ^a   Tilg, Herbert ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Cirrhosis; Inflammation; Insulin resistance

Indexed keywords

ADIPONECTIN; INSULIN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

ALCOHOLIC STEATOHEPATITIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HEPATIC VEIN; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER CIRRHOSIS; LIVER METABOLISM; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VEIN; PORTAL VEIN; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION;

ADIPONECTIN; ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL; CASE-CONTROL STUDIES; CHRONIC DISEASE; FATTY LIVER; FATTY LIVER, ALCOHOLIC; FEMALE; GASTROINTESTINAL AGENTS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER; LIVER CIRRHOSIS; LIVER DISEASES; MALE; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC;

EID: 24144497040     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2005.01543.x     Document Type: Article

References (37)

1. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995; 270: 26746-9.
2. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996; 271: 10697-703.
3. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996; 221: 286-9.
4. Havel PJ. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes 2004; 53 (Suppl. 1): S143-51.
5. Berg AH, Combs TP, Du XL, Brownlee M, Scherer P. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7: 947-53.
6. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 2001; 108: 1875-81.
7. Yamauchi T, Kamon J, Waki H et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-6.
8. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2002; 290: 1084-9.
9. Bruun JM, Lihn AS, Verdich C et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 2003; 285: E527-33.
10. Fasshauer M, Kralisch S, Klier M et al. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2003; 301: 1045-50.
11. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett 2001; 507: 142-6.
12. Delporte ML, Funahashi T, Takahashi M, Matsuzawa Y, Brichard SM. Pre- and post-translational negative effect of beta-adrenoceptor agonists on adiponectin secretion: in vitro and in vivo studies. Biochem J 2002; 367: 677-85.
13. Halleux CM, Takahashi M, Delporte ML et al. Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. Biochem Biophys Res Commun 2001; 288: 1102-7.
14. Yamauchi T, Kamon J, Ito Y et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762-9.
15. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91-100.
16. Tietge UJ, Boker KH, Manns MP, Bahr MJ. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Am J Physiol Endocrinol Metab 2004; 287: E82-9.
17. Kaser A, Ludwiczek O, Waldenberger P, Jaschke W, Vogel W, Tilg H. Endotoxin and its binding proteins in chronic liver disease: the effect of transjugular intrahepatic portosystemic shunting. Liver 2002; 22: 380-7.
18. Tilg H, Jalan R, Kaser A et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 2003; 38: 419-25.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
20. Perseghin G, Caumo A, Mazzaferro V et al. Assessment of insulin sensitivity based on a fasting blood sample in men with liver cirrhosis before and after liver transplantation. Transplantation 2003; 76: 697-702.
21. Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A, Carmena R. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 2003; 26: 3320-5.
22. Kaser S, Moschen A, Cayon A et al. Adiponectin and its receptors in nonalcoholic steatohepatitis. Gui 2004; 54: 117-21
23. Masaki T, Chiba S, Tatsukawa H et al. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology 2004; 40: 177-84.
24. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004; 40: 46-54.
25. Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-5.
26. Bugianesi E, Pagotto U, Manini R et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 2005; 90: 3498-504.
27. Pagano C, Soardo G, Esposito W et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol 2005; 152: 113-8.
28. Yokoyama H, Hirose H, Ohgo H, Saito I. Inverse association between serum adiponectin level and transaminase activities in Japanese male workers. J Hepatol 2004; 41: 19-24.
29. Havel PJ. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol 2002; 13: 51-9.
30. Hotta K, Funahashi T, Arita Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-9.
31. Petrides AS, DeFronzo RA. Glucose and insulin metabolism in cirrhosis. J Hepatol 1989; 8: 107-14.
32. Kaser S, Foger B, Waldenberger P et al. Transjugular intrahepatic portosystemic shunt (TIPS) augments hyperinsulinemia in patients with cirrhosis. J Hepatol 2000; 33: 902-6.
33. Tilg H, Wilmer A, Vogel W et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992; 103: 264-74.
34. Ludwiczek O, Kaser A, Novick D et al. Plasma levels of interleukin-18 and interleukin-18 binding protein are elevated in patients with chronic liver disease. J Clin Immunol 2002; 22: 331-7.
35. Maeda N, Shimomura I, Kishida K et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002; 8: 731-7.
36. Tacke F, Wustefeld T, Horn R et al. High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J Hepatol 2005; 42: 666-73.
37. Oshima K, Nampei A, Matsuda M et al. Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun 2005; 331: 520-6.